Catalogue Number: AB02055-23.0-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | Human α/β T Cell Receptor (TCR) |
| Shipping Condition: | Blue Ice |
| Unit(s): | 200 ug |
| Host name: | Rabbit |
| Clone: | BMA031 |
| Isotype: | IgG |
| Immunogen: | The original antibody was generated by immunizing mice with human perihperal blood T-lymphocytes. |
| Application: | FACS, FC, IF, IP, Blk |
Purified
Recombinant Monoclonal
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
This antibody is recomended for detection of viable human αβ+ TCR lymphocyte. It is highly effective in modulating immune reactions and is capable of activating human T lymphocytes in vito (PMID: 3092794). Double immunofluorescence staining was used to ascertain that this antibody does not cross react with γδ+ TCR cells. FACS analysis confirmed that BMA031 did not react with γδ+ TCR cells. BMA031 successfully precipitates TCR αβ/CDR complex (PMID: 1704361). BMA031 in conjugation with triple drug induction treatment in kidney-transplanted patients showed no side effects and reduction in graft rejections (PMID: 2978369). A clinical phase II trial administered 50 mg of murine anti-human alpha/beta-TCR mAb (BMA 031) intravenously on the day of, as well as 2 and 4 days after, cadaveric donor renal transplantation in combination with a CsA/prednisone regimen. After a minimum of 30 months follow-up, the actual allograft survival rate was 87% in the BMA-treated group compared with 68% in the control cohort (PMID: 8009591).Humanized version of this antibody BMA 031-EUCIV3 is found to have 2.5 times less affinity than its murine parent, however the ability to cause antibody dependent cell-mediated cytolysis was significantly enhanced (PMID: 1836485).
This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques.